Quantcast
Last updated on April 24, 2014 at 1:21 EDT

Latest Amaranth Stories

2013-02-06 12:25:47

SUNNYVALE, Calif., Feb. 6, 2013 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with the neurodegeneration and apoptosis centered around its patented therapeutic protein MANF, today announced that OneMedPlace Research has released an update to its initial research report on the Company, with a specific focus on data released on Amarantus' lead drug candidate MANF in a standard...

2013-01-31 08:29:28

SUNNYVALE, Calif., Jan. 31, 2013 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with the neurodegeneration and apoptosis centered around its patented therapeutic protein MANF, today announced it has secured an additional $1.4 million of financing commitments through an amendment of the initial Convertible Note with Dominion Capital. The original $600,000 note, dated November 14,...

2012-11-19 08:27:33

SUNNYVALE, Calif., Nov. 19, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that President & CEO Gerald Commissiong issued a letter to shareholders as detailed below. Dear Shareholders, I thank you for the trust you have placed in our management team. We fully respect the...

2012-11-14 16:25:53

SUNNYVALE, Calif., Nov. 14, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced it has secured over $1.1 million in funding through two separate transactions. Proceeds will be used to provide funding for the Company's lead asset, Mesencephalic-Astrocyte-derived Neurotrophic Factor...

2012-11-09 20:22:04

SUNNYVALE, Calif., Nov. 9, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS) is issuing corrections to a press release dated November 7 regarding data from a study into MANF, funded by The Michael J. Fox Foundation (MJFF). To clarify remarks in the original release, MJFF does not agree with Amarantus' statements that, to-date, reported behavioural pre-clinical data were positive, and that histology data confirm re-innervation of the striatum due to MANF delivery. MJFF reserves...

2012-10-17 07:27:00

SUNNYVALE, Calif. and SPRINGFIELD, Mass., Oct. 17, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments for brain-related disorders including Parkinson's disease and Traumatic Brain Injuries (TBI) centered on its unique proprietary anti-apoptotic therapeutic protein known as MANF, today announced a Translational Research Grant award from the University of Massachusetts' Pioneer Valley Life Sciences Institute's Center of...

2012-10-10 07:28:11

SUNNYVALE, Calif., Oct. 10, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centred on its proprietary anti-apoptotis therapeutic protein MANF, today provided the following update to shareholders from its President & CEO Gerald E. Commissiong: "The fundamental progress the Company has made since our First Annual CEO Letter was released in May has been quite...

2012-09-24 02:26:48

SUNNYVALE, Calif., Sept. 24, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCBB: AMBS), a California-based development-stage biotechnology developing new treatments and diagnostics for Parkinson's disease (PD) centered around its patented therapeutic protein MANF, today announced the release of a 2-page research report by OneMedPlace Research. The report can be found at http://www.onemedplace.com/reports/Amarantus_Research_Analysis.pdf. The report states: "Treatment with MANF...

2012-06-07 23:02:28

Bayer CropScience confirms event dates for 2012. Research Triangle Park, NC (PRWEB) June 07, 2012 In a growing number of fields across this vast country, herbicide-resistant weeds are towering over valuable crops, their branches dripping thousands of stubborn seeds that if left unchecked will infest fields and choke out profits for years to come. In the Mid-South, crews of workers are chopping pigweed that resemble small trees. These all too common sights in the Mid-South are threatening to...

2012-01-25 08:00:00

The geographical and health sciences website EurekaMag.com publishes insights into specific subjects of all areas of geographical and health science. The latest reviews cover Aurora borealis which are the Northern Lights caused by radiation emitted as light from atoms in the upper atmosphere as they are hit by fast-moving electrons and protons, and bayam which is amaranth, a herb with approximately 60 species and inflorescences and foliage ranging from purple to red and gold. The latest...


Latest Amaranth Reference Libraries

31_e597242657fa45c1bc1750f2e22e44ca
2005-07-12 10:26:47

The cockscombs are edible and ornamental plants named for their brightly colored flower heads, comprising the genus Celosia of the family Amaranthaceae (subfamily Amaranthoideae). They are similar in appearance and uses to the amaranths. Silver cockscomb is grown as a leaf vegetable and pseudo-cereal, especially in West and Central Africa and Southeast Asia. It is also the most important leaf vegetable of southern Nigeria. The crested cockscomb is a common garden ornamental plant in...

More Articles (1 articles) »